Electro-Capacitive Cancer Therapy (ECCT), a non-invasive electric-field–based treatment used alongside standard therapies, showed meaningful benefits in a case series of six patients with advanced lung adenocarcinoma, including both EGFR-mutant and EGFR-wild-type profiles. Across the cohort, five patients experienced partial tumor response and one achieved stable disease, with imaging demonstrating notable tumor regression and improved clinical condition. ECCT was well tolerated with no severe adverse events, even when combined with chemotherapy, immunotherapy, radiotherapy, or targeted EGFR-TKI treatments. These results indicate that ECCT may enhance the effectiveness of conventional treatments across molecular subtypes while maintaining a favorable safety profile. Conclusion: This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes.
Understanding Electric Field Therapy
This section goes beyond discussing ECCT, offering a comprehensive overview of electric field therapy. Its purpose is to educate and share insights on the broader applications of electric field therapy, drawing from diverse global sources such as news articles, expert opinions, research studies, educational materials, professional guidance, and more.
ClinicalResearch Articles
ECCT Modulates the Therapeutic Landscape for Advanced Lung Adenocarcinoma: A Case Series Demonstrating Efficacy Across EGFR-Mutant and Wild-Type Subtypes
Authors
:
- Shinichiro Akiyama, Warsito P. Taruno, Edi Sukur, Ahmad Novian Rahman Hakim, Wamid Antaboga, Dessy Arianty
Non-contact electric fields’ effect on TNF-a in glioblastoma cell line: An experimental study
The experimental findings demonstrate that the non-contact electric field successfully triggers key cellular responses in the U87-MG glioblastoma cell line. Specifically, there was a visible increase of Tumor Necrosis Factor alpha (TNF-\alpha) after just 24 hours of exposure across all tested voltages (10, 30, and 50 Vpp). This initial surge is significant, as established electric field therapies are known to induce immunogenic cell death (ICD), which involves the stimulation of inflammatory cytokines like TNF-α. This mechanism is thought to originate from endoplasmic reticulum stress. Furthermore, pathways downstream of TNF-α are believed to cause apoptosis, a desired process of physiological cell death. While the TNF-α level decreased after 24 hours, this reduction might be associated with the elevation of apoptosis markers, such as Annexin V, observed in studies of related electric field therapies. These promising initial biological insights confirm that the ECCT device engages important therapeutic pathways, underscoring the necessity for future research to fully elucidate the exact biomolecular pathway involved.
Authors
:
- Rizki Meizikri, Irwan Barlian Immadoel Haq, Wihasto Suryaningtyas, Purwati Purwati, Muhammad Arifin Parenrengi, Joni Wahyuhadi, Budi Utomo, Warsito Taruno
Capacitance Electric Fields (CEFs) Represent a Groundbreaking Approach in Cancer Therapy
Capacitance Electric Fields (CEFs) uses the principles of physics to selectively target and disrupt cancer cells while sparing healthy tissues. Cancer cells are uniquely vulnerable due to their altered membranes, which have distinct electrical and structural properties compared to normal cells. By applying precisely controlled electric fields, CEFs destabilize these membranes, creating tiny, temporary pores that disrupt the cancer cell’s balance of ions and other molecules, ultimately leading to cell death. Unlike traditional treatments like chemotherapy and radiation, which often harm healthy tissues and cause significant side effects, CEF therapy offers a non-invasive and highly targeted solution. Its ability to complement existing therapies—such as enhancing the delivery of chemotherapy drugs or boosting immune responses—positions CEFs as a transformative tool in the fight against cancer, offering patients a more precise and gentle treatment option.
Authors
:
- Bilgin Keserci
Current Challenges in Cancer Therapy: A Biophysical Perspective on Electric Field-Based Strategies
Cancer treatment faces significant challenges due to tumor diversity, therapy resistance, immune system evasion, and toxicity. Conventional methods like chemotherapy, radiation, and immunotherapy are often limited by the tumor’s ability to adapt through genetic mutations and metabolic changes. The tumor microenvironment further complicates treatment by blocking drug penetration, suppressing immunity, and sustaining cancer stem cells, leading to disease progression. To overcome these hurdles, electric field therapies have emerged as a promising alternative, targeting cancer cells differently from traditional approaches. By altering cell voltage, ion transport, and structural integrity, these therapies selectively disrupt cancer growth while sparing healthy tissues. They also improve treatment effectiveness by stabilizing blood vessels, reducing low-oxygen areas, and boosting immune responses. Additionally, electric fields may help prevent metastasis, enhance drug delivery, and improve access to the brain by temporarily opening the blood-brain barrier. As research progresses, combining electric fields with existing treatments could offer a non-invasive, more precise strategy to improve cancer outcomes.
Authors
:
- Bilgin Keserci, Muhammed Hamza Muslumanoglu, Chandran Nadarajan
ECCT: Physical Therapy for Cancer – clinical report
国際抗老化再生医療学会雑誌 第 6 巻（20−33）2024
By Shinichiro Akiyama, MD, PhD, FACP
Cancer gene; Immunotherapy Expert
Clinical Oncology, McGill University, CANADA
Faculty of Science and Technology, Keio University, JAPAN
Mechanism of Action
Electro Capacitive Cancer Therapy (ECCT) employs low-voltage, medium-frequency electric fields to disrupt mitotic progression by inducing microtubule depolymerization, ultimately triggering apoptosis in cancer cells while sparing normal tissues. By interfering with the electrostatic forces that stabilize spindle formation during cell division, ECCT selectively targets proliferating malignant cells without the systemic toxicity associated with conventional therapies such as chemotherapy and radiotherapy.
Preclinical Evidence
In vitro and in vivo studies have demonstrated ECCT’s efficacy in suppressing tumor growth, with research indicating a 28–39% reduction in cancer cell proliferation and significant tumor shrinkage in murine models. Further investigations have revealed ECCT-mediated downregulation of IL-18 and CCL-2, key inflammatory cytokines implicated in tumor progression, as well as p53-independent p21 pathway activation leading to apoptosis in osteosarcoma cells. These findings highlight ECCT’s potential as a targeted, non-cytotoxic oncologic intervention.
Clinical Evidence
ECCT has shown promising outcomes in multiple malignancies, including glioblastoma multiforme (GBM), breast cancer, lung cancer, and lymphoma, as evidenced by a retrospective analysis of 5,195 patients. A Kaplan-Meier survival analysis in GBM patients revealed a median overall survival (OS) of 28.9 months for ECCT-treated individuals versus 15.6 months for those receiving Temozolomide (TMZ) alone, suggesting superior efficacy with ECCT. Furthermore, ECCT’s safety profile was highly favorable, with no high-grade systemic toxicity reported and only mild, localized discomfort in select cases.
Tumor Response Classification
Electrical Capacitance Volume Tomography (ECVT) has enabled the stratification of tumor responses into five categories, with soft, medium-to-high-grade tumors exhibiting the most favorable responses to ECCT, while highly aggressive phenotypes necessitate extended monitoring due to rapid metastatic potential. These findings suggest that ECCT may be particularly effective in certain tumor subtypes, warranting further investigation into
patient selection criteria.
Future Directions
As a non-invasive, well-tolerated therapeutic modality, ECCT holds significant potential for patients with advanced, refractory, or chemotherapy-intolerant malignancies. Future research will focus on optimizing treatment parameters, investigating synergies with immune checkpoint inhibitors, and conducting large-scale, randomized clinical trials to establish ECCT as a paradigm-shifting oncologic intervention with broad clinical applicability.
If validated through further studies, ECCT could redefine the landscape of cancer treatment by offering a novel, mechanistically distinct alternative to conventional cytotoxic therapies.
Authors
:
- Shinichiro Akiyama, Manato Akiyama, Warsito Purwo Taruno, Edi Sukur, Ahmad Novian Rahman Hakim, Wamid Antaboga
Capacitance Electric Field Therapy: A New Frontier in Non-Invasive Cancer Treatment
This publication review explores the emerging cancer therapy modality known as Capacitance Electric Field (CEF), a non-invasive approach utilizing low-frequency alternating electric fields to selectively disrupt mitosis in tumor cells while sparing normal tissues. Through preclinical and early clinical studies, CEF has demonstrated tumor growth inhibition via multiple mechanisms including interference with microtubule polymerization, mitotic spindle disruption, and apoptosis induction. The article highlights real-world clinical applications across diverse malignancies such as glioblastoma multiforme, breast cancer, non-small cell lung cancer, and neuroendocrine tumors, documenting improved radiological response, disease control, and in some cases, survival.
Mechanistically, CEF exerts anti-tumor effects by altering cell membrane polarization, perturbing mitotic chromosomal alignment, and modulating immune checkpoints such as PD-L1 and IL-18 expression. Unlike treatments targeting specific mutations, CEF’s biophysical mechanism provides a broad-spectrum therapeutic potential, especially valuable for patients with limited molecular-targeted options. The integration of CEF with conventional therapies, including chemotherapy and radiotherapy, is also discussed, with emphasis on the importance of further randomized controlled trials to validate efficacy, optimize protocols, and expand clinical utility.
Authors
:
- Bünyamin KAPLAN , Bilgin KESERCİ
Role of Electric Fields in Integrated Complementary Cancer Therapy
The article explores the potential of electric fields as a novel and promising approach in integrated complementary cancer therapy, emphasizing their advantages over conventional therapies, the challenges associated with current cancer treatments, and the need for continued research to optimize the application of electric fields in cancer therapy.
Electric fields offer a promising avenue for cancer therapy, with multiple mechanisms contributing to their therapeutic effects. By disrupting membrane integrity, interfering with cellular electrical properties, arresting mitosis, enhancing traditional therapies, and modulating the tumor microenvironment, electric fields provide a multifaceted approach to cancer treatment. Ongoing research and clinical trials are essential to fully elucidate these mechanisms and optimize the use of electric fields in oncology.
Authors
:
- Bilgin Keserci, Yugarajah Asokumaran, Nadarajan Chandran.
The effect of exposure to electro-capacitive cancer treatment on JNK2α2 expression and the number of glioblastoma cells
This study explores the effects of ECCT on glioblastoma (GBM), an extremely aggressive form of brain cancer. ECCT uses low-intensity, medium-frequency electrostatic wave energy to target cancer cells. The research focuses on JNK2α2, a protein that plays a role in tumor growth, and looks at how ECCT influences its levels and the number of GBM cells in a laboratory setting. The results show that ECCT can significantly decrease both the amount of JNK2α2 and the number of GBM cells, suggesting it could be a promising complementary treatment option.
Key Findings:
- Significant Reduction in JNK2α2 Expression: ECCT exposure significantly decreased JNK2α2 expression in U-87MG GBM cells. The reduction was particularly notable at higher intensities (30 and 50 PPV) and longer exposure durations (48 and 72 hours), suggesting that ECCT effectively disrupts the MAPK signaling pathway, which is crucial for cell proliferation and survival.
- Decrease in Cell Viability and Proliferation: Prolonged ECCT exposure led to a significant reduction in GBM cell counts. The most substantial reduction in cell proliferation was observed at 72 hours, indicating that longer durations of ECCT enhance its anti-proliferative effects.
- Mechanism of Action: ECCT disrupts the JNK2α2 signaling pathway, which is part of the MAPK pathway involved in cell proliferation and survival. This disruption leads to decreased proliferation and increased apoptosis of GBM cells. Additionally, ECCT affects receptor tyrosine kinase (RTK) interactions on the cell membrane, disrupting downstream signaling pathways like Ras/Raf/MEK/p42/44MAPK, which are essential for cell growth and survival. This disruption inhibits tumor cell proliferation and promotes cell death.
- Therapeutic Implications: ECCT offers a non-invasive method to target GBM cells, potentially reducing the need for aggressive surgical interventions. The significant reduction in cell proliferation with ECCT highlights its potential as a complementary therapy to existing treatments.
- Safety and Efficacy: The study demonstrates the safety of ECCT, with no adverse effects on normal cell function observed. The efficacy of ECCT in reducing GBM cell proliferation suggests promising therapeutic outcomes, particularly when used in conjunction with other treatment modalities.
- Clinical Implications: ECCT offers a promising non-invasive alternative to traditional GBM treatments, which often involve invasive procedures with significant side effects. ECCT could be effectively combined with other treatments to enhance therapeutic outcomes. For example, combining ECCT with chemotherapeutic agents could improve overall efficacy by targeting multiple pathways simultaneously. Ensuring the safety of ECCT is crucial for its clinical application, and this study highlights its safety profile, minimizing concerns about adverse effects.
Authors
:
- Muhammad Arifin Parenrengi, Irwan Barlian Immadoel Haq, Joni Wahyuhadi, Ditto Darlan, Budi Utomo, Purwati, Warsito Purwo Taruno.
The effect of non‐contact electro capacitive cancer therapy on Tumorigenic agent‐ induced rat breast tumor angiogenesis
Researchers have explored a new cancer treatment called ECCT and found that it can affect blood vessel growth in breast cancer tumours. This treatment uses electrical fields to target tumours without harming normal breast tissue. The study showed that ECCT increases certain proteins that help form blood vessels in tumours, which might help fight cancer in a new way.
Key Findings:
- Impact on Angiogenic Gene Expression in Normal Breast Tissues: ECCT exposure did not significantly alter the expression of Hif1α, Sp1, and Vegfa genes in normal breast tissues. This indicates that ECCT does not induce or suppress angiogenesis-related gene expression in non-cancerous cells, suggesting its safety for normal tissues.
- Impact on Angiogenic Gene Expression in Tumorigenic agent-Induced Tumors: There was a significant increase in Vegfa expression in the INT (induced non-therapy) group, reflecting the tumor’s angiogenic response to Tumorigenic agent induction. Vegfa expression was notably lower in the IT (induced therapy) group following ECCT treatment, suggesting that ECCT effectively downregulates Vegfa expression in tumor tissues and potentially inhibits tumor angiogenesis. In addition, Hif1α expression significantly increased in the INT group, indicating a hypoxic response and angiogenic drive in the tumor. No significant change in Hif1α expression in the IT group post-ECCT treatment suggests that ECCT might mitigate the hypoxic conditions or the tumor’s response to hypoxia.
- Vegfr2 Gene Expression and Protein Levels: Vegfr2 gene expression remained unchanged with ECCT exposure, supporting that ECCT does not adversely affect angiogenesis in normal tissues. Vegfr2 expression was significantly higher in the IT group compared to the INT group, suggesting that while ECCT downregulates Vegfa, it upregulates Vegfr2, indicating a shift towards Vegfr2-mediated angiogenesis. Immunohistochemistry confirmed increased Vegfr2 protein levels in the IT group, corresponding with the gene expression data. This suggests enhanced angiogenesis via a different pathway facilitated by Vegfr2.
- Angiogenesis Assessment: The IT group showed a higher number of blood vessels compared to the INT group, indicating that ECCT impacts tumor vasculature. This might be due to the shift towards Vegfr2-mediated angiogenesis, resulting in enhanced blood vessel formation.
- Safety and Non-Invasive Nature of ECCT: The lack of significant changes in angiogenic gene expression in normal breast tissues under ECCT exposure suggests its safety and minimal impact on non-cancerous cells.The downregulation of Vegfa and stabilization of Hif1α in tumor tissues indicate that ECCT can counteract the tumor’s angiogenic response without inducing significant hypoxia.
- Mechanism of Action: The study indicates a shift in angiogenic pathways from Vegfa to Vegfr2 under ECCT. Vegfr2 is involved in stable and mature blood vessel formation, which might support immune cell infiltration and anti-tumor immunity. By downregulating primary angiogenic drivers and promoting Vegfr2 pathways, ECCT alters the tumor’s angiogenic landscape, potentially making it more susceptible to immune-mediated tumor suppression.
- Therapeutic Implications: ECCT offers a non-invasive alternative to traditional therapies, reducing the need for surgical interventions and associated complications. ECCT can be combined with existing treatments, enhancing overall therapeutic efficacy and reducing side effects by modulating angiogenic pathways.
Authors
:
- Endah Sri Palupi, Bambang Retnoaji, Pudji Astuti, Firman Alamsyah, Warsito Purwo Taruno, Rarastoeti Pratiwi.
Alternating Current-Electric Field Inducing Chorio Allantoic Membrane (CAM) Angiogenesis through Exogenous Growth Factor Intervention
This study explores a fascinating new way to promote the formation of new blood vessels, which is crucial for healing and recovery in many medical conditions. Scientists used a special device to create tiny electric fields and combined it with a natural growth substance called basic fibroblast growth factor (bFGF) in a chick embryo model. They found that while the electric fields alone didn’t do much, the combination with bFGF led to a significant increase in new blood vessel growth. This breakthrough could lead to new treatments for conditions like heart disease, where improving blood flow is essential, and certain cancers, where controlling blood vessel growth is crucial. This research shows how innovative technologies can work together with natural processes to improve health and recovery.
Key Findings:
- No Impact on Normal Angiogenesis: AC-EF exposure did not significantly affect angiogenesis in non-bFGF-induced groups (NINT and NIT), indicating that intermediate-frequency AC-EF at 150 kHz and 18 Vpp is safe for normal physiological processes.
- Enhanced Angiogenesis with bFGF: Significant promotion of angiogenesis was observed in the bFGF-induced AC-EF group (IT), suggesting a synergistic effect of bFGF induction and AC-EF treatment.
- Highest Number of New Blood Vessels: The IT group, which received both bFGF induction and AC-EF treatment, exhibited the highest number of new blood vessels (36.67±10.48) and the highest angiogenesis response (51.95±43.04%), significantly more than other groups (P<0.05).
- Statistical Significance: The IT group’s increase in new blood vessels was statistically significant compared to the other groups, as indicated by different superscript letters in the analysis.
- VEGFA Gene Expression: No significant upregulation of VEGFA gene expression was observed in the NIT group (non-bFGF-induced, AC-EF exposure), indicating that AC-EF alone does not significantly alter VEGFA expression. Slight, but not statistically significant, upregulation of VEGFA was observed in the IT group (bFGF-induced, AC-EF exposure), suggesting that other factors might also contribute to the enhanced angiogenic response.
- Safety of AC-EF: The lack of effect on normal angiogenesis in non-bFGF-induced groups supports the safety profile of AC-EF for clinical applications, ensuring no adverse effects on healthy tissue.
- Therapeutic Potential: The enhanced angiogenic response in the IT group highlights the potential of AC-EF combined with growth factors like bFGF for therapeutic strategies aimed at promoting vascular growth in conditions such as chronic wounds, ischemic tissues, and certain cardiovascular diseases.
- Context-Dependent Effects of AC-EF: The study demonstrates that the presence of exogenous growth factors like bFGF is crucial in determining the pro-angiogenic effect of AC-EF, contrasting with previous findings of AC-EF’s anti-angiogenic effects in other contexts.
- Implications for Regenerative Medicine: The findings suggest potential applications of AC-EF in regenerative medicine, such as wound healing and the treatment of ischemic conditions, by promoting tissue repair and regeneration.
Authors
:
- Endah Sri Palupi, Bambang Retnoaji, Pudji Astuti, Firman Alamsyah, Warsito Purwo Taruno, and Rarastoeti Pratiwi.